LINC02900: A Promising Drug Target for Cancer (G340073)

Target Name: LINC02900

NCBI ID: G340073

LINC02900

Other Name(s): C5orf66-AS2 | long intergenic non-protein coding RNA 2900 | Long intergenic non-protein coding RNA 2900 | CTC-349C3.2

LINC02900: A Promising Drug Target for Cancer

LINC02900 (C5orf66-AS2) is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. LINC02900 is a key regulator of the cell cycle and has been shown to play a role in the development and progression of cancer.

The discovery of LINC02900 as a potential drug target stems from a study by researchers at the University of California, San Diego, who identified its potential role in the regulation of cell cycle progression in cancer cells. The researchers found that LINC02900 was highly expressed in various types of cancer and that it was involved in the regulation of the G1/S transition, a critical step in the cell cycle that helps cells prepare for cell division.

In addition to its role in cell cycle regulation, LINC02900 has also been shown to play a role in the development and progression of cancer. For example, a study by the same researchers found that LINC02900 was highly expressed in various types of cancer and that it was associated with poor prognosis in patients with these diseases.

The potential drug target status of LINC02900 is supported by several pieces of evidence. For example, a study by the University of California, San Diego found that LINC02900 was highly expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, a study by the same researchers found that LINC02900 was involved in the regulation of the G1/S transition and that this regulation was associated with the development and progression of cancer.

In conclusion, LINC02900 is a promising drug target for the treatment of various diseases, including cancer. Its role in cell cycle regulation and its association with the development and progression of cancer make it a promising target for drug development. Further research is needed to fully understand the potential mechanisms of LINC02900 as a drug target and to develop safe and effective treatments for a variety of diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 2900

The "LINC02900 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02900 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets